KSQ-4279   Click here for help

GtoPdb Ligand ID: 11964

Synonyms: example 143 [WO2020132269A1] | KSQ4279 | USP1-IN-1
Compound class: Synthetic organic
Comment: KSQ-4279 is a first-in-class, allosteric inhibitor of the cysteine protease ubiquitin specific peptidase 1 (USP1), that was developed by KSQ Therapeutics as a novel, orally bioavailable cancer therapeutic. It is proposed as a monotherapy or as an adjunct to PARP inhibitor drugs. Its chemical structure was disclosed at the AACR spring meeting in 2022.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 96.43
Molecular weight 534.21
XLogP 5.33
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ncnc(c1c1ncc2c(n1)n(nc2)Cc1ccc(cc1)c1nc(cn1C(C)C)C(F)(F)F)C1CC1
Isomeric SMILES COc1ncnc(C2CC2)c1c1nc2c(cnn2Cc2ccc(cc2)c2nc(cn2C(C)C)C(F)(F)F)cn1
InChI InChI=1S/C27H25F3N8O/c1-15(2)37-13-20(27(28,29)30)35-24(37)18-6-4-16(5-7-18)12-38-25-19(11-34-38)10-31-23(36-25)21-22(17-8-9-17)32-14-33-26(21)39-3/h4-7,10-11,13-15,17H,8-9,12H2,1-3H3
InChI Key KCBWAFJCKVKYHO-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
KSQ-4279 will be evaluated for efficacy in patients with advanced solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05240898 A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients With Advanced Solid Tumors Phase 1 Interventional KSQ Therapeutics, Inc.